Correspondence
![](/images/Oa.jpg)
Cost considerations in determining the affordability of adjuvant trastuzumab in breast cancer
Authors' affiliations
W Szpak, Rainbow Oncology' Amanzimtoti, South Africa
R P Abratt, Head of Clinical Governance, Independent Clinical Oncology Network; Emeritus Professor of Radiation Oncology, University of Cape Town, South Africa
Full Text
![](/images/icons/PDF.png)
Keywords
Cite this article
Article History
Date published: 2016-12-21
Article Views
Full text views: 1001
Comments on this article
*Read our policy for posting comments here